In vitro testing of daptomycin plus rifampin against methicillin-resistant Staphylococcus aureus resistant to rifampin Article

PMID: 19082221 Web of Science: 000262756400006
International Collaboration

Cited authors

  • Khasawneh, FaisalA.; Ashcraft, Deborah S.; Pankey, George A.


  • Objectives: To test for synergy between daptomycin (DAP) and rifampin (RIF) against RIF-resistant methicillin-resistant Staphylococcus aureus (MRSA) isolates.; Methods: Synergy testing using time-kill assay (TKA) was performed on 6 clinically, and genetically unique RIF-resistant MRSA isolates. The isolates were identified out of 489 (1.2%) samples collected during April 2003 to August 2006, from patients at the Ochsner Medical Center in New Orleans, Louisiana, United States of America.; Results: Synergy testing of DAP plus RIF by TKA showed that 5 isolates were indifferent, but one isolate was antagonistic.; Conclusion: Our in vitro study failed to demonstrate synergy between DAP plus RIF, against our RIF-resistant MRSA isolates. Clinical failure of this combination should prompt the clinician to consider antagonism, as one of the potential causes.

Publication date

  • 2008

Published in


International Standard Serial Number (ISSN)

  • 0379-5284

Start page

  • 1726

End page

  • 1729


  • 29


  • 12